Chondromyxoid Fibroma (CMF)
A rare, benign but locally aggressive bone tumour — most often seen around the knee in children and young adults. With modern surgery and adjuvants, long-term cure is the rule, not the exception.
What is Chondromyxoid Fibroma?
Chondromyxoid fibroma (CMF) is a rare, benign (non-cancerous) bone tumour made up of fibrous, cartilage-like (chondroid) and myxoid (mucoid) tissues. It accounts for less than 0.5% of all bone tumours and about 2% of benign bone tumours.2,5
Who gets CMF and where does it occur?
Average around 30 years; reported from 6 to 63
Slight female predominance
Pelvis, proximal tibia, distal femur — metaphysis of long bones
- • Most often in the metaphysis of long bones
- • Lower limbs around the knee most frequently affected
- • Upper limb involvement is extremely rare
What causes CMF?
The exact cause is unknown. Current research suggests:
- • No specific chromosomal abnormality has been identified
- • May involve myofibroblastic differentiation driven by transforming growth factor β-1
- • Contains the Sox9 gene, which directs cartilage formation
Despite being benign, CMF can be locally aggressive — growing steadily and damaging surrounding bone if left untreated.
What are the symptoms of CMF?
How is CMF diagnosed?
- • X-ray: well-defined, eccentric lytic lesion with smooth scalloped borders
- • Classic 'soap-bubble' appearance with bone expansion and cortical thinning
- • MRI: homogeneous low-intensity pattern; better detail of soft-tissue involvement
- • Helps distinguish CMF from chondrosarcoma and chondroblastoma
- • Image-guided core needle biopsy is essential for confirmation
- • Characteristic lobular pattern with stellate-shaped cells
- • Myxoid or chondroid background matrix
- • Expert pathology review is critical to avoid confusion with chondrosarcoma, chondroblastoma or aneurysmal bone cyst
Treating Chondromyxoid Fibroma in a Young Patient
A real-world account of how a young patient with chondromyxoid fibroma was successfully treated with limb-preserving surgery at The Orthoncology Clinic — covering diagnosis, the surgical plan and return to full function.
Watch on YouTube →Current treatment options for CMF
Surgery is the primary treatment because of the high recurrence risk without appropriate management. The choice of procedure depends on tumour size, location and aggressiveness.2,4
Surgical options
- • Thorough intralesional curettage of the tumour cavity
- • Filled with autograft, allograft or PMMA bone cement
- • Joint-preserving and biological reconstruction
- • Very low recurrence when performed properly
Advanced adjuvants
Mechanically extends the cavity 1–2 mm to remove microscopic disease.
Thermal ablation of cavity walls to destroy residual tumour cells.
Chemical adjuvant that further reduces local recurrence rates.
Treatment success rates
Can CMF come back after treatment?
- • Younger patients (especially under 15) — higher risk
- • Curettage alone — much higher than with grafting
- • More myxoid tissue and cellular atypia on pathology
- • Most recurrences happen within 2 years of surgery
- • Late recurrences can occur up to 19 years later
- • Overall average 15–20% — much lower with optimal treatment
Can CMF become cancerous?
Most reported malignant transformations have occurred after radiotherapy, which is why radiation is generally avoided. Without radiation, transformation is extremely rare and may represent misdiagnosis.
- • Rapid growth or change in symptoms
- • New, severe pain
- • Imaging changes suggesting aggressive behaviour
What's my outlook with CMF?
- • Regular monitoring for a minimum of 2 years (longer in selected cases)
- • Periodic X-rays to detect recurrence early
- • Clinical examination to assess function and symptoms
Which treatment approach is best for me?
- • First-time diagnosis
- • Tumour is accessible
- • Bone can be preserved
- • You want to maintain original bone structure
- • Tumour is in an expendable bone (e.g. fibula)
- • Previous treatment has failed
- • Very large or aggressive tumour
- • Complete cure is a priority over bone preservation
What should I expect during recovery?
- • Weight-bearing restrictions for 3–6 weeks (depends on location)
- • Gradual return to activities over 3–4 months
- • Physical therapy for larger reconstructions
- • Regular follow-up with X-rays and clinical exams
- • Infection (rare with proper care)
- • Graft failure (uncommon with modern techniques)
- • Recurrence (significantly reduced with optimal treatment)
- • Stiffness (usually temporary)
When should I contact my doctor?
- • Sudden increase in pain at the surgical site
- • Signs of infection — fever, redness, drainage
- • New swelling or changes in the treated area
- • Any concerns about healing or recovery
- • Attend all scheduled appointments
- • Report any new symptoms promptly
- • Follow activity restrictions as advised
References
- Retrospective evaluation of 31 chondromyxoid fibroma cases, 2024
- NCBI PMC — Comprehensive study of CMF treatment outcomes, 2024
- Chondromyxoid fibroma with malignant potential — review, 2023
- NCBI PMC — Management strategies and recurrence rates in CMF, 2014
- Pathology Outlines — Chondromyxoid fibroma diagnostic and treatment guidelines
Important Notice: This information is provided for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
Always seek the advice of a qualified orthopaedic oncologist or healthcare provider with any questions about chondromyxoid fibroma or any other medical condition. Treatment decisions are complex and depend on tumour size, location, patient age, activity level and individual circumstances.
In case of emergency or urgent symptoms such as severe pain, suspected fracture, signs of infection or neurological changes, seek immediate medical attention or contact your local emergency services.
The Orthoncology Clinic is committed to providing current, evidence-based information while emphasising the importance of professional medical consultation for all health-related decisions.